Evaluation of liver injury in multiple sclerosis patients receiving pulsed steroid therapy
Copyright © 2022 Elsevier B.V. All rights reserved..
OBJECTIVES: There is a paucity of literature about the methylprednisolone induced liver injury in multiple sclerosis (MS) patients. In this study, we intended to investigate the incidence, severity, and risk factors for liver injury in MS patients treated with pulsed methylprednisolone therapy.
METHODS: This is a prospective observational study on MS patients treated with methylprednisolone pulses. All MS subjects with relapses who were referred to Sina Hospital between May 2020 to May 2021 were included in the study. They were evaluated for the demographic, clinical characteristics, and liver function tests. Liver injury was diagnosed if there was an elevation of serum aminotransferase levels above the upper normal limit (45 IU/L).
RESULTS: A total of 314 individuals participated in the study. The prevalence of liver injury after treatment with pulsed methylprednisolone therapy was 2.86%. None of the cases with liver injury were severe. Univariate regression analysis demonstrated that the patients with liver injury had a significantly higher frequency of hyperlipidemia (p: 0.002), alcohol abuse (p: 0.021), and non-alcoholic fatty liver disease (NAFLD) (p: 0.005) compared to those without liver injury. Multivariate regression analysis showed that hyperlipidemia (p: 0.04, odds ratio (OR): 6.31), and history of alcohol abuse (p: 0.007, OR: 36.71) were significantly associated with liver injury.
CONCLUSIONS: Our study highlights the importance of a close follow-up of the liver function tests in MS patients following pulsed methylprednisolone therapy, particularly in patients with NAFLD, hyperlipidemia, and history of alcohol-abusing.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Multiple sclerosis and related disorders - 65(2022) vom: 01. Sept., Seite 103968 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Namaei, Pooria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alcohol |
|---|
| Anmerkungen: |
Date Completed 07.09.2022 Date Revised 07.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.msard.2022.103968 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343001241 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343001241 | ||
| 003 | DE-627 | ||
| 005 | 20231226015413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.msard.2022.103968 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1143.xml |
| 035 | |a (DE-627)NLM343001241 | ||
| 035 | |a (NLM)35779371 | ||
| 035 | |a (PII)S2211-0348(22)00479-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Namaei, Pooria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of liver injury in multiple sclerosis patients receiving pulsed steroid therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.09.2022 | ||
| 500 | |a Date Revised 07.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a OBJECTIVES: There is a paucity of literature about the methylprednisolone induced liver injury in multiple sclerosis (MS) patients. In this study, we intended to investigate the incidence, severity, and risk factors for liver injury in MS patients treated with pulsed methylprednisolone therapy | ||
| 520 | |a METHODS: This is a prospective observational study on MS patients treated with methylprednisolone pulses. All MS subjects with relapses who were referred to Sina Hospital between May 2020 to May 2021 were included in the study. They were evaluated for the demographic, clinical characteristics, and liver function tests. Liver injury was diagnosed if there was an elevation of serum aminotransferase levels above the upper normal limit (45 IU/L) | ||
| 520 | |a RESULTS: A total of 314 individuals participated in the study. The prevalence of liver injury after treatment with pulsed methylprednisolone therapy was 2.86%. None of the cases with liver injury were severe. Univariate regression analysis demonstrated that the patients with liver injury had a significantly higher frequency of hyperlipidemia (p: 0.002), alcohol abuse (p: 0.021), and non-alcoholic fatty liver disease (NAFLD) (p: 0.005) compared to those without liver injury. Multivariate regression analysis showed that hyperlipidemia (p: 0.04, odds ratio (OR): 6.31), and history of alcohol abuse (p: 0.007, OR: 36.71) were significantly associated with liver injury | ||
| 520 | |a CONCLUSIONS: Our study highlights the importance of a close follow-up of the liver function tests in MS patients following pulsed methylprednisolone therapy, particularly in patients with NAFLD, hyperlipidemia, and history of alcohol-abusing | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Alcohol | |
| 650 | 4 | |a Hyperlipidemia | |
| 650 | 4 | |a Liver injury | |
| 650 | 4 | |a Methylprednisolone | |
| 650 | 4 | |a Multiple sclerosis | |
| 650 | 7 | |a Methylprednisolone |2 NLM | |
| 650 | 7 | |a X4W7ZR7023 |2 NLM | |
| 700 | 1 | |a Ghadiri, Fereshteh |e verfasserin |4 aut | |
| 700 | 1 | |a Jamali, Raika |e verfasserin |4 aut | |
| 700 | 1 | |a Azimi, Amir Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Farhadi Shabestari, Hamid Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Vahabizad, Fahimeh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Multiple sclerosis and related disorders |d 2012 |g 65(2022) vom: 01. Sept., Seite 103968 |w (DE-627)NLM219118388 |x 2211-0356 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2022 |g day:01 |g month:09 |g pages:103968 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.msard.2022.103968 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2022 |b 01 |c 09 |h 103968 | ||